{"id":"NCT00135330","sponsor":"AstraZeneca","briefTitle":"An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus","officialTitle":"An Evaluation of the Metabolic Effects of Exenatide, Rosiglitazone, and Exenatide Plus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2005-08-26","resultsPosted":"2009-08-28","lastUpdate":"2015-04-07"},"enrollment":137,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"exenatide","otherNames":["Byetta"]},{"type":"DRUG","name":"rosiglitazone","otherNames":["Avandia"]}],"arms":[{"label":"Exenatide Arm","type":"EXPERIMENTAL"},{"label":"Exenatide plus Rosiglitazone Arm","type":"EXPERIMENTAL"},{"label":"Rosiglitazone Arm","type":"EXPERIMENTAL"}],"summary":"This protocol is designed to evaluate the metabolic effects of adding exenatide, rosiglitazone, or both to an existing regimen of metformin in subjects with inadequate glycemic control.","primaryOutcome":{"measure":"Change in ASIiAUC During a Hyperglycemic Clamp Test.","timeFrame":"20 weeks","effectByArm":[{"arm":"Exenatide","deltaMin":643.4,"sd":106.71},{"arm":"Exenatide Plus Rosiglitazone","deltaMin":686.41,"sd":103.7},{"arm":"Rosiglitazone","deltaMin":786.12,"sd":113.6}],"pValues":[{"comp":"OG001 vs OG002","p":"0.282"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":19,"countries":["United States"]},"refs":{"pmids":["22236356","20107105"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3},"commonTop":["Nausea","Vomiting","Dizziness","Oedema peripheral","Diarrhoea"]}}